(19)
(11) EP 2 433 954 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
13.05.2015 Bulletin 2015/20

(45) Mention of the grant of the patent:
25.02.2015 Bulletin 2015/09

(21) Application number: 11003883.3

(22) Date of filing: 06.09.2006
(51) International Patent Classification (IPC): 
C07K 14/47(2006.01)
C12Q 1/68(2006.01)
 C07K 16/30(2006.01)

(54)

Identification of tumor-associated antigens for diagnosis and therapy

Identifikation Tumor-assoziierter Antigene für Diagnose und Therapie

Identification des antigènes associés aux tumeurs pour diagnostics et thérapie

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK RS

(30) Priority: 12.09.2005 EP 05019786

(43) Date of publication of application:
28.03.2012 Bulletin 2012/13

(60) Divisional application:
15153951.7

(62) Application number of the earlier application in accordance with Art. 76 EPC:
06791878.9 / 1924600

(73) Proprietors:
  • BioNTech AG
    55131 Mainz (DE)
  • Johannes Gutenberg-Universität Mainz, vertreten durch den Präsidenten
    55122 Mainz (DE)

(72) Inventors:
  • Sahin, Ugur
    55116 Mainz (DE)
  • Türeci, Özlem
    55116 Mainz (DE)
  • Koslowski, Michael
    85764 Oberschleißheim (DE)
  • Usener, Dirk
    65193 Wiesbaden (DE)

(74) Representative: Schnappauf, Georg et al
ZSP Patentanwälte Partnerschaftsgesellschaft Radlkoferstrasse 2
81373 München
81373 München (DE)


(56) References cited: : 
WO-A-2004/065629
 US-A1- 2004 203 037
   
  • COCCHIA M ET AL: "PLAC1, an Xq26 Gene with Placenta-Specific Expression", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 68, no. 3, 15 September 2000 (2000-09-15), pages 305-312, XP004437833, ISSN: 0888-7543 & DATABASE UniProt 1 March 2001 (2001-03-01), retrieved from EBI Database accession no. Q9HBJ0 & DATABASE EMBL 14 October 2000 (2000-10-14), retrieved from EBI Database accession no. AF234654
  • DATABASE EMBL 7 September 2002 (2002-09-07), XP002363480, retrieved from EBI Database accession no. AK075086
  • PARDOLL M: "CANCER VACCINES", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 4, no. 5, May 1998 (1998-05), pages 525-531, XP002921126, ISSN: 1078-8956
  • SAHIN U ET AL: "Serological identification of human tumor antigens", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, vol. 9, no. 5, October 1997 (1997-10), pages 709-716, XP004313590, ISSN: 0952-7915
  • BRUGGEN VAN DER P ET AL: "A GENE ENCODING AN ANTIGEN RECOGNIZED BY CYTOLYTIC T LYMPHOCYTES ON A HUMAN MELANOMA", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 254, 13 December 1991 (1991-12-13), pages 1643-1647, XP000604921, ISSN: 0036-8075
  • NAKATA YUJI ET AL: "Nucleic acid modulation of gene expression: Approaches for nucleic acid therapeutics against cancer", CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, vol. 15, no. 2, 2005, pages 163-182, XP009063123, ISSN: 1045-4403
  • DATABASE Probe [Online] NCBI; 22 June 2005 (2005-06-22), XP002668456, Database accession no. Pr139971.1
  • DATABASE Probe [Online] NCBI; 22 June 2005 (2005-06-22), XP002668457, Database accession no. Pr179963.1
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).